First Tracks Biotherapeutics (TRAX) Stock Forecast
TRAX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 12 analysts
- Price target
- $74.17 average of analyst targets
- Upside to target
- +115.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.92
- 52-week range
- $11.61 – $47.92
TRAX analyst ratings
12 analystsNumber of analysts at each rating.
TRAX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TRAX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.89 | −$1.01 | −$0.63 | — | — | 10 |
| Current fiscal year (2026) | −$4.03 | −$4.54 | −$3.20 | — | — | 11 |
| Next fiscal year (2027) | −$3.62 | −$4.77 | −$2.39 | −$4.03 | +10.1% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TRAX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
TRAX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TRAX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.79 | −$0.87 | −$0.90 | −$0.89 | −$0.89 | +12.7% | 2 up · 5 down |
| Current fiscal year (2026) | −$3.60 | −$3.91 | −$4.10 | −$4.04 | −$4.03 | +11.9% | 2 up · 5 down |
| Next fiscal year (2027) | −$3.24 | −$3.36 | −$3.70 | −$3.58 | −$3.62 | +11.8% | 3 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TRAX earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; TRAX beat in 0 of 2.
What analysts expect from TRAX
12 analysts cover First Tracks Biotherapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $74.17, 115.2% above the latest close of $34.46. Analysts expect earnings of −$4.03 per share for 2026. For 2027 the average estimate is −$3.62 per share. First Tracks Biotherapeutics beat the EPS estimate in 0 of the last 2 quarters.
Related: TRAX income statement, TRAX key metrics, TRAX chart. See the TRAX stock overview for the latest quote and news.
TRAX forecast FAQ
What is First Tracks Biotherapeutics's price target?
The average analyst price target for First Tracks Biotherapeutics is $74.17, 115.2% above the latest close of $34.46.
Is First Tracks Biotherapeutics a buy, hold or sell?
Of 12 analysts covering First Tracks Biotherapeutics, 9 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is First Tracks Biotherapeutics's EPS forecast?
Analysts forecast −$4.03 per share for 2026 (range −$4.54 to −$3.20); for 2027 the estimate is −$3.62.
When does First Tracks Biotherapeutics report earnings?
First Tracks Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.92.
Does First Tracks Biotherapeutics usually beat earnings estimates?
First Tracks Biotherapeutics reported EPS at or above the analyst estimate in 0 of the last 2 quarters.